Ascendiant Capital Markets Estimates RenovoRx Q1 Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Ascendiant Capital Markets issued their Q1 2027 earnings per share estimates for RenovoRx in a report issued on Wednesday, April 8th. Ascendiant Capital Markets analyst E. Woo expects that the company will post earnings of ($0.06) per share for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $13.50 target price on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.40) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS and Q4 2027 earnings at ($0.05) EPS.

Several other research analysts have also recently commented on the stock. Wall Street Zen cut shares of RenovoRx from a “hold” rating to a “strong sell” rating in a report on Saturday, April 4th. Weiss Ratings restated a “sell (e+)” rating on shares of RenovoRx in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of RenovoRx in a report on Wednesday, April 8th. Finally, JonesTrading upgraded RenovoRx to a “strong-buy” rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.25.

RenovoRx Stock Up 1.0%

Shares of RNXT opened at $1.03 on Tuesday. RenovoRx has a twelve month low of $0.70 and a twelve month high of $1.45. The stock has a market capitalization of $46.40 million, a P/E ratio of -3.22 and a beta of 1.22. The company has a 50 day moving average of $0.95 and a 200-day moving average of $0.99.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.42 million. RenovoRx had a negative return on equity of 119.77% and a negative net margin of 994.48%.During the same period last year, the company earned ($0.40) earnings per share.

Institutional Trading of RenovoRx

Institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new stake in shares of RenovoRx during the 3rd quarter worth approximately $154,000. Bleichroeder LP increased its stake in RenovoRx by 11.4% in the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after acquiring an additional 61,379 shares during the last quarter. Geode Capital Management LLC raised its position in RenovoRx by 9.9% during the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after purchasing an additional 31,730 shares in the last quarter. Wealthspire Advisors LLC acquired a new position in RenovoRx during the fourth quarter valued at approximately $212,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in RenovoRx during the second quarter worth $98,000. Institutional investors own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.